CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre
Laboratories has been awarded the "Prix Galien International" Prize
in the "Best Product for a Rare/Orphan Disease" category for
EBVALLO® (tabelecleucel), indicated as monotherapy for the
treatment of patients with post-transplant lymphoproliferative
disorder positive for Epstein-Barr virus (EBV+ PTLD) who have
received at least one prior treatment.
During the same ceremony, EBVALLO® received the "Prix Galien"
Italy Award in the Advanced Therapy Medicinal Product category.
These two exceptional recognitions follow the awarding of EBVALLO®
for the "Prix Galien France" on December
2023
As a symbol of scientific rigor, excellence, and innovation, the
"Prix Galien International" awards remarkable recent health
innovations available to the public, following an evaluation done
by an independent committee of experts. Today this prize exists in
fifteen countries, its reputation and influence have made it the
most prestigious distinction in the medical field. Through this
prize, the jury honors EBVALLO®, thanks to its innovative
manufacturing process and mechanism of action. It offers rapid and
lasting clinical results in over 50% of cases, in a rare disease
with a particularly unfavorable prognosis, leading to significant
morbidity and mortality.
This award highlights the innovation capacity of Pierre Fabre
Laboratories in oncology, one of its priority areas of development,
and its ability to establish successful collaborations, such as the
one with Atara Biotherapeutics (ATARA), an American biotech
company. A global agreement was signed in December 2023, providing Pierre Fabre
Laboratories with the EBVALLO® development, manufacturing, and
commercialization rights all over the world. EBVALLO® was approved
by the European Medicines Agency (EMA) in December 2022, and to date, this promising new
treatment is marketed in Germany
and Austria. In Europe, EBVALLO® is available to patients as
part of an Early Access Program since July
2023.
"We are very proud to receive this award, which we dedicate
to the patients. It is a recognition of the major therapeutic
advancement that EBVALLO® represents for patients with a rare
cancer and a very unfavorable prognosis, who until now had
significant unmet needs. This cancer, which affects a few hundred
people worldwide each year, resonates perfectly with our purpose:
every time we take care for a single person, we make the whole
world better." said Éric Ducournau, CEO of the Pierre
Fabre Laboratories.
CONTACT: Laurence MARCHAL, laurence.marchal@pierre-fabre.com
PDF -
https://mma.prnewswire.com/media/2444819/PR_PRIX_GALIEN_INTERNATIONAL_PRO_EN.pdf
Photo -
https://mma.prnewswire.com/media/2444818/Galien_ED_NP_CS_remise_finale.jpg
Logo -
https://mma.prnewswire.com/media/2416854/4775613/Pierre_Fabre_Laboratories.jpg
View original content to download
multimedia:https://www.prnewswire.co.uk/news-releases/pierre-fabre-laboratories-receives-the-galien-international-prize-for-ebvallo-the-first-allogeneic-immunotherapy-for-patients-with-a-rare-cancer-302179008.html